The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective evaluation of circulating cell-free DNA sequencing in patients with metastatic renal cell carcinoma treated with pazopanib plus abexinostat.
 
Jim Leng
No Relationships to Disclose
 
Armand Harb
No Relationships to Disclose
 
Kamran Abri
No Relationships to Disclose
 
Ilaria Mastroserio
No Relationships to Disclose
 
Anne Reinert
No Relationships to Disclose
 
Jennifer A. Grabowsky
No Relationships to Disclose
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Terence W. Friedlander
Honoraria - Sanofi
Consulting or Advisory Role - Astellas Pharma; Prometheus
Research Funding - Aragon Pharmaceuticals (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Janssen
Travel, Accommodations, Expenses - Astellas Pharma
 
Amy M. Lin
No Relationships to Disclose
 
Richard Burnham Lanman
Employment - Guardant Health; Veracyte
Stock and Other Ownership Interests - Guardant Health; Veracyte
 
Kimberly C. Banks
Employment - Ambry Genetics; Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Rahul Raj Aggarwal
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)